Chi-Med plans to submit marketing authorization application (MAA) for surufatinib for treatment of pancreatic and non-pancreatic neuroendocrine tumours (NET) following scientific advice from European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)

Company announced the completed SANET-ep (non-pancreatic NET) and SANET-p (pancreatic NET) studies, along with existing data from surufatinib in U.S. non-pancreatic and pancreatic NET patients, could form basis to support a MAA, planned for 2021, following submission to FDA.

SPS commentary:

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor and fibroblast growth factor receptor.

Biospace Inc.